Evaluation of Guideline-Recommended Combined Antiretroviral Treatment Regimens in Commercially-Insured Patients Living in the United States Between 2007 and 2009
2016
- 240Usage
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage240
- Downloads129
- Abstract Views111
Article Description
Background: Randomized clinical trials of combination antiretroviral therapy (cART) inform the use of specific antiretrovirals (ARV) and their combination for optimizing therapeutic efficacy. It is critical that patients have access to and receive the most appropriate first-line treatment.Objective: To examine factors that impact receiving initial guideline-recommended cART within a cohort of commercially insured patients in the United States (US)Research Design: A population based cohort study.Data Sources: A secondary administrative insurance claims database.Subjects: Employed, commercially insured individuals with HIV who were continuously eligible for insurance coverage from January 2007 through December 2009 and received a new ARV prescription.Measures: The primary outcome was defined as an initial claim for a prescription containing recommended cART consisting of two nucleoside reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor, protease inhibitor or an integrase strand transfer inhibitor. Modified Poisson adjusted multivariable models including patient demographic and provider characteristics evaluated predictors of receiving recommended cART.Results: Of the 2,115 patients with a new ARV claim, 59% were white and 71% were male with a median age of 42 years (Interquartile Range: 35-49). Overall, 76% of the population received recommended cART. Receiving care from an infectious disease specialist was the strongest predictor of receiving recommended cART (Risk Ratio: 1.37, 95% Confidence Interval (CI): 4 1.30, 1.43). Men, those with less education, younger individuals, and no comorbidities were also more likely to receive recommended cART (p<0.01).Conclusions: Many HIV-infected patients that are in clinical care are not prescribed recommended cART. Increased communication and training of healthcare providers is necessary to insure patients receive a durable first-line regimen.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know